VX-702 is a third generation inhibitor of p38 mitogen-activated protein (MAP) kinases, binding to both p38alpha and p38beta (Kd = 3.7 and 17 nM, respectively) in an ATP-competitive fashion. It inhibits IL-6, IL-1beta, and TNF-alpha production in LPS-primed blood with IC50 values of 59, 122, and 99 ng/ml,...

VX-702 is a second-generation, orally active mitogen-activated protein kinase (MAPK) p38 inhibitor. It is being tested for the potential treatment of inflammation, rheumatoid arthritis and cardiovascular diseases. Solubility: Soluble in DMSO. Storage and Stability: May be stored at RT for short-term only. Long-term...

Soluble in DMSO or ethanol. The kinases called p38 MAP kinases (MAPKs) are intracellular, soluble serine-threonine kinases which belong to a large family of proteins that include the extracellular regulated kinases (ERKs) and c-Jun N-terminal kinases (JNKs). So far four p38 isoforms have been identified, namely...